155049-60-8 Usage
Derivative of 1H-1,2,4-triazole
2-(1H-1,2,4-triazol-3-yl)acetic acid hydrochloride is a chemical compound that is derived from 1H-1,2,4-triazole.
Used in pharmaceutical research and drug development
This compound is commonly used in pharmaceutical research and drug development due to its potential therapeutic properties.
Hydrochloride salt form
The compound is a hydrochloride salt form, which means it is often used in pharmaceutical formulations for improved stability and bioavailability.
Potential as a medication for various conditions
2-(1H-1,2,4-triazol-3-yl)acetic acid hydrochloride has been studied for its potential as a medication for various conditions, including neurological disorders and cancer.
Versatile and important compound in medicinal chemistry
The chemical structure of 2-(1H-1,2,4-triazol-3-yl)acetic acid hydrochloride makes it a versatile and important compound in the field of medicinal chemistry.
Potential applications in drug synthesis and development
Due to its unique properties and structure, the compound has potential applications in drug synthesis and development.
Check Digit Verification of cas no
The CAS Registry Mumber 155049-60-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,5,0,4 and 9 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 155049-60:
(8*1)+(7*5)+(6*5)+(5*0)+(4*4)+(3*9)+(2*6)+(1*0)=128
128 % 10 = 8
So 155049-60-8 is a valid CAS Registry Number.
155049-60-8Relevant articles and documents
Discovery of novel, highly potent, and selective matrix metalloproteinase (MMP)-13 inhibitors with a 1,2,4-triazol-3-yl moiety as a zinc binding group using a structure-based design approach
Nara, Hiroshi,Kaieda, Akira,Sato, Kenjiro,Naito, Takako,Mototani, Hideyuki,Oki, Hideyuki,Yamamoto, Yoshio,Kuno, Haruhiko,Santou, Takashi,Kanzaki, Naoyuki,Terauchi, Jun,Uchikawa, Osamu,Kori, Masakuni
, p. 608 - 626 (2017/02/05)
On the basis of a superposition study of X-ray crystal structures of complexes of quinazoline derivative 1 and triazole derivative 2 with matrix metalloproteinase (MMP)-13 catalytic domain, a novel series of fused pyrimidine compounds which possess a 1,2,4-triazol-3-yl group as a zinc binding group (ZBG) was designed. Among the herein described and evaluated compounds, 31f exhibited excellent potency for MMP-13 (IC50 = 0.036 nM) and selectivities (greater than 1,500-fold) over other MMPs (MMP-1, -2, -3, -7, -8, -9, -10, and -14) and tumor necrosis factor-α converting enzyme (TACE). Furthermore, the inhibitor was shown to protect bovine nasal cartilage explants against degradation induced by interleukin-1 and oncostatin M. In this article, we report the discovery of extremely potent, highly selective, and orally bioavailable fused pyrimidine derivatives that possess a 1,2,4-triazol-3-yl group as a novel ZBG for selective MMP-13 inhibition.
